+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Adrenocorticotropin/Cortisol and Arginine-Vasopressin Secretory Patterns in Response to Ghrelin in Normal Men

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          This study was performed in order to establish the secretory patterns and the possible relationships between the adrenocorticotropin (ACTH)/cortisol and arginine vasopressin (AVP) responses in normal men to the systemic administration of ghrelin, an endogenous ligand for the growth hormone secretagogue receptor. For this purpose, a bolus of 1 µg/kg ghrelin was injected intravenously in 9 normal men. AVP, ACTH and cortisol significantly rose in response to ghrelin injection; however, in all subjects the AVP rise preceded the ACTH/cortisol responses. In fact, the mean peak levels of AVP, ACTH and cortisol after ghrelin injection were observed at 15, 30 and 45 min, respectively. When peak AVP responses to ghrelin were considered together with ACTH and cortisol peak levels, highly significant positive correlations were observed (AVP and ACTH, r = 0.94, p < 0.001; AVP and cortisol, r = 0.92, p < 0.001). In conclusion, this study shows that the AVP response to ghrelin precedes the concomitant ACTH/cortisol rise and that these hormonal responses are highly positively correlated. These observations support the hypothesis that AVP mediates ghrelin-induced ACTH secretion in normal men.

          Related collections

          Most cited references 12

          • Record: found
          • Abstract: found
          • Article: not found

          A receptor in pituitary and hypothalamus that functions in growth hormone release.

          Small synthetic molecules termed growth hormone secretagogues (GHSs) act on the pituitary gland and the hypothalamus to stimulate and amplify pulsatile growth hormone (GH) release. A heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPC-R) of the pituitary and arcuate ventro-medial and infundibular hypothalamus of swine and humans was cloned and was shown to be the target of the GHSs. On the basis of its pharmacological and molecular characterization, this GPC-R defines a neuroendocrine pathway for the control of pulsatile GH release and supports the notion that the GHSs mimic an undiscovered hormone.
            • Record: found
            • Abstract: not found
            • Article: not found

            Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues

              • Record: found
              • Abstract: found
              • Article: not found

              Growth hormone-releasing peptide (GHRP).

               C Bowers (1998)
              Growth hormone-releasing peptides and non-peptides (GHRPs. GHRP-GHS) are a new chemical class of GH secretagogues with a chemistry that ranges from small synthetic peptides to peptidomimetics. They release GH in animals and humans by a unique dual and complementary action on the hypothalamus and pituitary. Although the present GHRPs are of unnatural origin, evidence by a number of investigators is gradually accumulating to support that GHRP reflects the GH-releasing action of a new natural hypothalamic hormone yet to be isolated and identified. Despite the de novo origin of GHRP, a major reason for the persistent investigation is because of the possible practical diagnostic and therapeutic value in humans as well as the potential theoretical value of new insight into the physiological regulation of GH secretion.

                Author and article information

                S. Karger AG
                July 2005
                06 July 2005
                : 81
                : 2
                : 103-106
                Departments of aInternal Medicine and Biomedical Sciences, and bPublic Health, University of Parma, Parma, Italy
                85541 Neuroendocrinology 2005;81:103–106
                © 2005 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 1, References: 23, Pages: 4
                Original Paper


                Comment on this article